RHYTHM PHARMACEUTICALS, INC.

Pharmaceutical Preparations·BOSTON, MA·FY end 12/31·CIK 1649904

CEO Pay Ratio

36:1

David P. Meeker

CEO Total Comp

$17.5M

David P. Meeker

Median Employee

$484,876

Revenue

$189.8M

FY 2025

Net Income

-$196.5M

FY 2025

Free Cash Flow

-$116.6M

FY 2025

Net Margin

-103.6%

Insider Net (180d)

-$2.7M

0 buys / 24 sales

CEO Pay Accountability

CEO comp as % of net income

-8.93%

For every $1,000 of profit, $-89.27 flows to the CEO.

CEO comp as % of buybacks

—

No buyback data for the most recent fiscal year.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$189.8M	$130.1M	$77.4M	—	—
Gross Profit	—	—	—	—	—	—
Operating Income	-$192.0M	-$265.5M	-$184.4M	-$179.2M	-$170.1M
Net Income	-$196.5M	-$260.6M	-$184.7M	-$181.1M	-$69.6M
Operating CF	-$115.7M	-$113.9M	-$136.2M	-$173.4M	-$146.0M
Capex	$953.0K	—	$47.0K	$281.0K	$434.0K
Free Cash Flow	-$116.6M	—	-$136.2M	-$173.7M	-$146.4M
Buybacks	—	—	—	—	—	—
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	-101.2%	-204.0%	-238.1%	—	—
Net Margin	-103.6%	-200.3%	-238.5%	—	—
FCF Margin	-61.5%	—	-175.9%	—	—
R&D / Revenue	88.2%	182.9%	174.3%	—	—
Effective Tax	-0.3%	-0.1%	-0.3%	—	—
Debt / Equity	0.73	4.98	—	—	—
Buybacks / FCF	—	—	—	—	—	—

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
David P. MeekerChief Executive Officer	$807.7K	$8.3M	$7.7M	$759.5K	$14.0K	$17.5M
Hunter C. SmithChief Financial Officer	$540.5K	$2.9M	$2.4M	$338.0K	$14.0K	$6.2M
Yann MazabraudExecutive Vice President,	$557.2K	$2.8M	$2.3M	$344.7K	$70.3K	$6.1M
Jennifer LeeExecutive Vice President,	$531.6K	$2.6M	$2.1M	$293.0K	$14.0K	$5.6M
Alastair GarfieldChief Scientific Officer	$505.4K	$2.1M	$1.5M	$287.0K	$14.0K	$4.4M